Excimer laser atherectomy combined with drug-coated balloon angioplasty for the treatment of chronic obstructive femoropopliteal arterial disease.
balloon angioplasty
drug-coated balloon
excimer laser atherectomy
femoropopliteal artery
occlusion
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
29
05
2019
accepted:
22
11
2019
entrez:
28
2
2020
pubmed:
28
2
2020
medline:
28
2
2020
Statut:
ppublish
Résumé
The aim of the present retrospective study was to evaluate the feasibility, safety and the primary results following application of excimer laser atherectomy (ELA) combined with adjunctive drug-coated balloon angioplasty (DCBA) as the first-line endovascular treatment for patients with chronic obstructive femoropopliteal arterial disease. The baseline characteristics and angiographic variables of all patients who underwent ELA for stable chronic obstructive femoropopliteal arterial disease at Tianjin First Central Hospital (Tianjin, China) between May and December 2017 were collected. Information on clinical characteristics, including the 12-month primary patency rate, technical success rate, procedural success rate, bailout stenting rate, target lesion revascularization and major adverse events, was obtained following review of the patients' medical records. A descriptive analysis was performed on all variables. Kaplan-Meier curves were plotted for the primary patency rate. The present study included 17 consecutive patients (age, 68.9±7.4 years; 94.1% males) who were followed up for 12 months after the intervention. Adjunctive BA was performed in 100% of the cases. The occlusion length was 23.3±8.9 cm (range, 5.6-40.5 cm). The technical success rate was 100% and the procedural success rate was 88.2%. Bailout stenting was required in 5 of the 17 patients (29.4%) and the 12-month primary patency rate was 82.4%. The clinically driven target lesion revascularization rate was 5.9% at 12 months. An embolic protection device was used in 23.5% of the patients. The following adverse events were reported: Distal embolization requiring treatment, 5.9% (1 patient with embolic protection device); and flow-limiting dissection requiring treatment, 5.9%. In the present study, there were no major adverse events (all-cause death, unplanned major amputation or target lesion revascularization) at 30 days after the intervention. Therefore, ELA combined with adjunctive DCBA for the treatment of chronic obstructive femoropopliteal arterial disease appears to be safe, practicable and associated with a high procedural success rate; furthermore, endoluminal-driven atherectomy may effectively reduce the requirement for stent placement in the lower limb arteries and is associated with long-term patency.
Identifiants
pubmed: 32104245
doi: 10.3892/etm.2019.8362
pii: ETM-0-0-8362
pmc: PMC7027043
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1887-1895Informations de copyright
Copyright: © Liu et al.
Références
Clin Med Insights Cardiol. 2015 Feb 24;8(Suppl 2):23-8
pubmed: 25780342
J Endovasc Ther. 2009 Jun;16(3):261-9
pubmed: 19642788
J Cardiovasc Surg (Torino). 2013 Jun;54(3):359-65
pubmed: 23138610
J Endovasc Ther. 2006 Feb;13(1):1-11
pubmed: 16445313
JACC Cardiovasc Interv. 2013 Dec;6(12):1295-302
pubmed: 24239203
JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):92-101
pubmed: 25499305
Circulation. 2015 Feb 3;131(5):495-502
pubmed: 25472980
Catheter Cardiovasc Interv. 2012 Jun 1;79(7):1188-93
pubmed: 22234869
J Endovasc Ther. 2009 Apr;16(2 Suppl 2):II82-97
pubmed: 19624076
Eur J Vasc Endovasc Surg. 2007 Dec;34(6):702-8
pubmed: 17920306
J Endovasc Ther. 2008 Aug;15(4):390-8
pubmed: 18729564
Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75
pubmed: 17140820
J Vasc Surg. 2013 Sep;58(3):682-6
pubmed: 23755977
J Vasc Surg. 2006 Aug;44(2):333-8
pubmed: 16890864
Ann Surg. 2008 Oct;248(4):519-28
pubmed: 18936564
J Vasc Surg. 2000 Jan;31(1 Pt 2):S1-S296
pubmed: 10666287
Eur J Vasc Endovasc Surg. 2010 Feb;39(2):234-8
pubmed: 19939709
Circulation. 2006 Aug 15;114(7):688-99
pubmed: 16908785
Catheter Cardiovasc Interv. 2007 May 1;69(6):910-9
pubmed: 17377972
Eur J Vasc Endovasc Surg. 2005 Jun;29(6):613-9
pubmed: 15878540
J Endovasc Ther. 2018 Feb;25(1):81-88
pubmed: 29219030
Circulation. 2007 May 29;115(21):2745-9
pubmed: 17502568
Circulation. 2007 Jul 17;116(3):285-92
pubmed: 17592075
Circ Cardiovasc Interv. 2010 Jun 1;3(3):267-76
pubmed: 20484101
Cardiovasc Revasc Med. 2012 Jul-Aug;13(4):224-7
pubmed: 22575073
N Engl J Med. 2006 May 4;354(18):1879-88
pubmed: 16672699
Circulation. 2008 Sep 23;118(13):1358-65
pubmed: 18779447
J Vasc Surg. 1997 Sep;26(3):517-38
pubmed: 9308598
Vasc Endovascular Surg. 2013 Apr;47(3):179-91
pubmed: 23448976
J Endovasc Ther. 2001 Apr;8(2):156-66
pubmed: 11357976
N Engl J Med. 2008 Feb 14;358(7):689-99
pubmed: 18272892
Am J Cardiol. 2009 Apr 1;103(7):923-9
pubmed: 19327417
Vasc Endovascular Surg. 2006 Aug-Sep;40(4):268-74
pubmed: 16959719
JACC Cardiovasc Interv. 2014 Apr;7(4):411-5
pubmed: 24630884
Ultrasound Med Biol. 1992;18(5):433-40
pubmed: 1509618
J Vasc Surg. 2011 Mar;53(3):658-66; discussion 667
pubmed: 21257284
J Invasive Cardiol. 2014 Jul;26(7):333-7
pubmed: 24993991
N Engl J Med. 2015 Jul 9;373(2):145-53
pubmed: 26106946
J Vasc Surg. 2010 Mar;51(3):673-8
pubmed: 20206811
J Endovasc Ther. 2009 Dec;16(6):665-75
pubmed: 19995111
J Endovasc Ther. 2014 Feb;21(1):34-43
pubmed: 24502482
J Endovasc Ther. 2016 Feb;23(1):52-7
pubmed: 26511896
J Cardiovasc Surg (Torino). 2012 Aug;53(4):487-94
pubmed: 22854529